Roche R&D Spending Surge Reflects In-House Innovation, M&A Prices
‘Costs Being Squeezed Everywhere’ To Fund R&D
A surprise surge in Roche's R&D spending this year reflects high quality in-house innovation opportunities as well as high prices for external M&A targets, management said.
You may also be interested in...
Pfizer Recruits Chief Development Officer William Pao From Roche R&D Team
William Pao will oversee Pfizer's global product development organization, while Roche appointed Hans Clevers to take over from Pao as head of Roche’s pRED.
Roche Gives The Stage To A New Generation Of Cancer Drugs
With big oncology losses largely in the rearview mirror, Roche is trying to sell investors on its next wave of cancer drugs; R&D overview pushes message of pipeline renewal.
Outside Oncology: 6 Updates From Roche's Pharma Investor Day
Management updated investors on M&A strategy, US drug pricing reform and R&D investment.